InMed Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA Pre-IND Meeting for INM-089 (Dry AMD) | 31 Dec 2026 |
| Expected Closing of Mentari Therapeutics Merger | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Short-Term Investments Quarterly5.2MTarget: Maintain sufficient capital to fund operations through key regulatory milestones
Quarterly Net Loss from Continuing Operations Quarterly-3MTarget: Minimize cash burn during pipeline transition
Watch Items
- Consummation of the Mentari Therapeutics MergerTrigger: Shareholder and regulatory approvals, and securing the minimum $150M (up to $290M) pre-closing financingAction: Monitor SEC Form S-4 filings, shareholder vote outcomes, and closing announcements expected in H2 2026
- FDA Pre-IND Meeting for INM-901 (Alzheimer's Disease)Trigger: Scheduled for Q3 2026Action: Review regulatory feedback regarding IND-enabling study designs and requirements for Phase 1 clinical trial initiation in 2027
- FDA Pre-IND Meeting for INM-089 (Dry AMD)Trigger: Scheduled for Q4 2026Action: Evaluate FDA guidance on preclinical package and CMC optimization prior to IND submission
- Wind-down of BayMedica Commercial OperationsTrigger: Substantial exit before fiscal year-end June 30, 2026Action: Verify complete cessation of discontinued commercial operations and final asset/liability disposition
Research as of 20 Jun 2026